Clinical Trials
31 trialsStudy of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University
ROME
Fondazione per la Medicina Personalizzata
I-STOP
University of Milano Bicocca
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Assistance Publique Hopitaux De Marseille
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
EDEN
Gruppo Oncologico Italiano di Ricerca Clinica
Nivokin
Philogen S.p.A.
Noelia
Clinica Universidad de Navarra, Universidad de Navarra
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Momotaro-Gene Inc.
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
National Cancer Center, Korea
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
ADIVO Lung
National University Hospital, Singapore
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Ella Therapeutics Ltd
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sheba Medical Center
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Northwestern University
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Ardigen
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Henan Cancer Hospital
NO3DEXPL
Nilogen Oncosystems
SQUINT
Fondazione Ricerca Traslazionale
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical University
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
Peking University Cancer Hospital & Institute
ModuLung
University Hospital Regensburg